Last reviewed · How we verify
Vehicle Diclofenac Sodium Topical Gel
Vehicle Diclofenac Sodium Topical Gel is a NSAID Small molecule drug developed by Amneal Pharmaceuticals, LLC. It is currently in Phase 3 development for Topical treatment of actinic keratosis.
Diclofenac sodium works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.
Diclofenac sodium works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain. Used for Topical treatment of actinic keratosis.
At a glance
| Generic name | Vehicle Diclofenac Sodium Topical Gel |
|---|---|
| Sponsor | Amneal Pharmaceuticals, LLC |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, an enzyme responsible for the production of prostaglandins, which are mediators of inflammation and pain. By inhibiting COX-2, diclofenac sodium reduces the production of prostaglandins, leading to decreased inflammation and pain. This mechanism of action is responsible for the therapeutic effects of diclofenac sodium in treating pain and inflammation.
Approved indications
- Topical treatment of actinic keratosis
Common side effects
- Skin burning sensation
- Skin irritation
Key clinical trials
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee" (PHASE3)
- Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee (PHASE3)
- A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis (PHASE3)
- Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses (PHASE3)
- Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis (PHASE2)
- A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis (PHASE1)
- Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle Diclofenac Sodium Topical Gel CI brief — competitive landscape report
- Vehicle Diclofenac Sodium Topical Gel updates RSS · CI watch RSS
- Amneal Pharmaceuticals, LLC portfolio CI
Frequently asked questions about Vehicle Diclofenac Sodium Topical Gel
What is Vehicle Diclofenac Sodium Topical Gel?
How does Vehicle Diclofenac Sodium Topical Gel work?
What is Vehicle Diclofenac Sodium Topical Gel used for?
Who makes Vehicle Diclofenac Sodium Topical Gel?
What drug class is Vehicle Diclofenac Sodium Topical Gel in?
What development phase is Vehicle Diclofenac Sodium Topical Gel in?
What are the side effects of Vehicle Diclofenac Sodium Topical Gel?
What does Vehicle Diclofenac Sodium Topical Gel target?
Related
- Drug class: All NSAID drugs
- Target: All drugs targeting COX-2
- Manufacturer: Amneal Pharmaceuticals, LLC — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Topical treatment of actinic keratosis
- Compare: Vehicle Diclofenac Sodium Topical Gel vs similar drugs
- Pricing: Vehicle Diclofenac Sodium Topical Gel cost, discount & access